{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:17:02Z","timestamp":1777601822976,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.gene.2023.147886","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:10:33Z","timestamp":1696932633000},"page":"147886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Distribution pattern of UGT1A6 and UGT2B7 gene polymorphism and its impact on the pharmacokinetics of valproic acid and carbamazepine: Prospective genetic association study conducted in Pakistani patients with epilepsy"],"prefix":"10.1016","volume":"892","author":[{"given":"Muhammad","family":"Saleh Faisal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niaz","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman M.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Almarshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2023.147886_b0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.gene.2023.147886_b0010","first-page":"185","volume":"54","author":"Beghi","year":"2020","journal-title":"The epidemiology of epilepsy."},{"key":"10.1016\/j.gene.2023.147886_b0015","first-page":"1","article-title":"Methods for extracting genomic DNA from whole blood samples: current perspectives","author":"Chacon-Cortes","year":"2014","journal-title":"J. Biorepos. Sci. Appl. Med."},{"key":"10.1016\/j.gene.2023.147886_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-198510020-00003","article-title":"Concentration-effect relationships of valproic acid","volume":"10","author":"Chadwick","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.gene.2023.147886_b0025","doi-asserted-by":"crossref","unstructured":"Chu, X.-M., Zhang, L.-F., Wang, G.-J., Zhang, S.-N., Zhou, J.-H. and Hao, H.-P.J.E.j.o.c.p., 2012b. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. 68, 1395-1401.","DOI":"10.1007\/s00228-012-1277-7"},{"key":"10.1016\/j.gene.2023.147886_b0030","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.gene.2023.147886_b0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2298\/VSP0905347D","article-title":"Determination of carbamazepine in serum and saliva samples by high performance liquid chromatography with ultraviolet detection","volume":"66","author":"\u0110or\u0111evi\u0107","year":"2009","journal-title":"Vojnosanit. Pregl."},{"key":"10.1016\/j.gene.2023.147886_b0040","doi-asserted-by":"crossref","unstructured":"Du, Z., Xu, H., Zhao, P., Wang, J., Xu, Q. and Liu, M.J.X., 2021. Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children. 51, 859-864.","DOI":"10.1080\/00498254.2021.1931554"},{"key":"10.1016\/j.gene.2023.147886_b0045","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.gene.2023.147886_b0050","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics\u2014drug disposition, drug targets, and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2023.147886_b0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.gene.2023.147886_b0060","doi-asserted-by":"crossref","unstructured":"Guo, Y., Hu, C., He, X., Qiu, F. and Zhao, L., 2012b. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug metabolism and pharmacokinetics, 1202290363-1202290363.","DOI":"10.2133\/dmpk.DMPK-11-RG-144"},{"key":"10.1016\/j.gene.2023.147886_b0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.gene.2023.147886_b0070","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gene.2023.147886_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/pgs.11.141","article-title":"Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization","volume":"13","author":"Hung","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gene.2023.147886_b0080","doi-asserted-by":"crossref","unstructured":"Inoue, K., Suzuki, E., Yazawa, R., Yamamoto, Y., Takahashi, T., Takahashi, Y., Imai, K., Koyama, S., Inoue, Y. and Tsuji, D.J.T.d.m., 2014. Influence of Uridine Diphosphate Glucuronosyltransferase 2B7\u2212 161C> T Polymorphism on the Concentration of Valproic Acid in Pediatric Epilepsy Patients. 36, 406-409.","DOI":"10.1097\/FTD.0000000000000012"},{"key":"10.1016\/j.gene.2023.147886_b0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0028-3886.152631","article-title":"Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy","volume":"63","author":"Jain","year":"2015","journal-title":"Neurol. India"},{"key":"10.1016\/j.gene.2023.147886_b0090","article-title":"Audit of 100 cases of epilepsy in a tertiary care hospital. Gomal","volume":"9","author":"Khan","year":"2011","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.gene.2023.147886_b0095","first-page":"594","article-title":"Epidemiology of epilepsy in Pakistan: review of literature. JPMA","volume":"53","author":"Khatri","year":"2003","journal-title":"J. Pak. Med. Assoc."},{"key":"10.1016\/j.gene.2023.147886_b0100","doi-asserted-by":"crossref","unstructured":"Kim, S.C., Kim, M.G.J.I.j.o.c.p. and therapeutics, 2019. A meta-analysis of the influence of UGT1A6 genetic polymorphisms on valproic acid pharmacokinetics. 57, 144.","DOI":"10.5414\/CP203357"},{"key":"10.1016\/j.gene.2023.147886_b0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00228-005-0940-7","article-title":"Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects","volume":"61","author":"Kim","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.gene.2023.147886_b0110","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.gene.2023.147886_b0115","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.gene.2023.147886_b0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome\u2026: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.gene.2023.147886_b0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.gene.2023.147886_b0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1474-4422(07)70127-8","article-title":"Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review","volume":"6","author":"Mac","year":"2007","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.gene.2023.147886_b0135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.gene.2023.147886_b0140","first-page":"747","article-title":"Carbamazepine 10, 11-epoxidation in human liver microsomes: influence of the CYP3A5* 3 polymorphism","volume":"72","author":"Miyata-Nozaka","year":"2017","journal-title":"Die Pharmazie- Int. J. Pharm. Sci."},{"key":"10.1016\/j.gene.2023.147886_b0145","doi-asserted-by":"crossref","unstructured":"Mohammadi, M.R., Ghanizadeh, A., Davidian, H., Mohammadi, M. and Norouzian, M.J.S., 2006. Prevalence of epilepsy and comorbidity of psychiatric disorders in Iran. 15, 476-482.","DOI":"10.1016\/j.seizure.2006.05.011"},{"key":"10.1016\/j.gene.2023.147886_b0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40291-013-0041-8","article-title":"The effect of uridine diphosphate glucuronosyltransferase (UGT) 1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach","volume":"17","author":"Munisamy","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.gene.2023.147886_b0155","doi-asserted-by":"crossref","unstructured":"Nandith, P., Adiga, U., Shenoy, V. and Adiga MN, S., 2021a. UGT1A6 and UGT2B7 gene polymorphism and its effect in pediatric epileptic patients on sodium valproate monotherapy. The Indian Journal of Pediatrics, 1-7.","DOI":"10.1007\/s12098-020-03565-9"},{"key":"10.1016\/j.gene.2023.147886_b0160","doi-asserted-by":"crossref","unstructured":"Nandith, P., Adiga, U., Shenoy, V. and Adiga MN, S.J.T.I.J.o.P., 2021b. UGT1A6 and UGT2B7 gene polymorphism and its effect in pediatric epileptic patients on sodium valproate monotherapy. 1-7.","DOI":"10.1007\/s12098-020-03565-9"},{"key":"10.1016\/j.gene.2023.147886_b0165","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1124\/dmd.107.019562","article-title":"Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2, 3-dihydroxycarbamazepine","volume":"36","author":"Pearce","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.gene.2023.147886_b0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/bs.apha.2018.04.004","article-title":"Pharmacogenetics in pain treatment","volume":"83","author":"Peir\u00f3","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.gene.2023.147886_b0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gene.2023.147886_b0180","doi-asserted-by":"crossref","unstructured":"Savic, I.J.E.N., 2014. Sex differences in human epilepsy. 259, 38-43.","DOI":"10.1016\/j.expneurol.2014.04.009"},{"key":"10.1016\/j.gene.2023.147886_b0185","first-page":"4513","article-title":"Effects of UGT1A3, UGT1A6, and UGT2B7 genetic polymorphisms on plasma concentration of valproic acid in south Chinese epilepsy patients","volume":"9","author":"Shen","year":"2016","journal-title":"Int. J. Clin. Exp. Path."},{"key":"10.1016\/j.gene.2023.147886_b0190","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.gene.2023.147886_b0195","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/FPC.0b013e328348c6f2","article-title":"PharmGKB summary: carbamazepine pathway","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.gene.2023.147886_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.119182","article-title":"Epilepsy control with carbamazepine monotherapy from a genetic perspective","volume":"429","author":"Ullah","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.gene.2023.147886_b0205","doi-asserted-by":"crossref","unstructured":"Ullah, S., Ali, N., Khan, A., Ali, S. and Nazish, H.R.J.F.i.N., 2018. The epidemiological characteristics of epilepsy in the province of Khyber Pakhtunkhwa, Pakistan. 9, 845.","DOI":"10.3389\/fneur.2018.00845"},{"key":"10.1016\/j.gene.2023.147886_b0210","doi-asserted-by":"crossref","unstructured":"Wang, Y. and Li, Z.J.T., 2020. Association of UGT2B7 and CaMK4 with response of valproic acid in Chinese children with epilepsy. 75, 261-270.","DOI":"10.1016\/j.therap.2019.07.003"},{"key":"10.1016\/j.gene.2023.147886_b0215","unstructured":"Wang, Y., Gao, L., Liu, Y.P., Huang, N.N., Xu, S.J. and Ma, D.J., 2010. Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan. Zhongguo dang dai er ke za zhi= Chinese journal of contemporary pediatrics 12, 429-432."},{"key":"10.1016\/j.gene.2023.147886_b0220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejps.2018.06.033","article-title":"Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors","volume":"122","author":"Xu","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.gene.2023.147886_b0225","doi-asserted-by":"crossref","unstructured":"Xu, S., Liu, L., Chen, Y., Liu, M., Lu, T., Wang, H., Liu, S., Zhao, M. and Zhao, L.J.E.J.o.C.P., 2018b. Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. 74, 583\u2013591.","DOI":"10.1007\/s00228-018-2414-8"},{"key":"10.1016\/j.gene.2023.147886_b0230","doi-asserted-by":"crossref","unstructured":"Zhang, H., Zhang, W., Li, Y., Yan, J., Zhang, J., Wang, B.J.B. and Development, 2018. Correlations between UGT2B7\u2217 2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients. 40, 100\u2013106.","DOI":"10.1016\/j.braindev.2017.09.004"},{"key":"10.1016\/j.gene.2023.147886_b0235","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1080\/21655979.2022.2036916","article-title":"Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population","volume":"13","author":"Zhao","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.gene.2023.147886_b0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/pgs-2022-0156","article-title":"Effects of UGT1A, CYP2C9\/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients","volume":"24","author":"Zheng","year":"2023","journal-title":"Pharmacogenomics"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111923007278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111923007278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:27:10Z","timestamp":1736375230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111923007278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":48,"alternative-id":["S0378111923007278"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2023.147886","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution pattern of UGT1A6 and UGT2B7 gene polymorphism and its impact on the pharmacokinetics of valproic acid and carbamazepine: Prospective genetic association study conducted in Pakistani patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2023.147886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"147886"}}